Opdivo and Scar - a phase IV clinical study of FDA data

Summary:

Scar is reported as a side effect among people who take Opdivo (nivolumab), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Yervoy, and have Malignant melanoma.

The phase IV clinical study analyzes which people have Scar when taking Opdivo. It is created by eHealthMe based on reports of 56,294 people who have side effects when taking Opdivo from the FDA, and is updated regularly.

What is Opdivo?

Opdivo has active ingredients of nivolumab. eHealthMe is studying from 56,331 Opdivo users. Check the latest studies of Opdivo.

What is Scar?

Scar is found to be associated with 1,231 drugs and 1,431 conditions by eHealthMe. Check the latest studies of Scar.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

56,294 people reported to have side effects when taking Opdivo.
Among them, 27 people (0.05%) have Scar.

Among these 27 people:

How long have people been on Opdivo when they have Scar? *

What is the gender of people who have Scar when taking Opdivo? *

female: 52 %
male: 48 %

What is the age of people who have Scar when taking Opdivo? *

What are other drugs people take besides Opdivo? *

What are other side effects people have besides Scar? *

Headache (pain in head): 12 people, 44.44%
Fever: 12 people, 44.44%
Dry Mouth: 11 people, 40.74%
Pain: 10 people, 37.04%
Pancreatitis (inflammation of pancreas): 9 people, 33.33%
Weight Loss: 9 people, 33.33%
Rashes (redness): 9 people, 33.33%
Oedema (fluid collection in tissue): 9 people, 33.33%
Skin Hyperpigmentation (disorders affect the colour of your skin): 9 people, 33.33%
General Physical Health Deterioration (weak health status): 9 people, 33.33%

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 12 people, 44.44%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 9 people, 33.33%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 11.11%
Retroperitoneal Cancer (cancer between the peritoneum and the posterior abdominal wall): 2 people, 7.41%
Renal Cell Carcinoma (a kidney cancer): 2 people, 7.41%
Malignant Melanoma Stage Iii (cancer has spread to one or more lymph nodes): 2 people, 7.41%
Choroid Melanoma (cancer tumour arise from the blood-vessel layer ""choroid"" beneath the retina): 2 people, 7.41%
Blood Glucose Increased: 2 people, 7.41%
Thyroid Diseases: 1 person, 3.70%
Stress And Anxiety: 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Opdivo and have Scar?

- Check whether Scar is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Opdivo:

Opdivo (56,331 reports)

Scar treatments and more:

Scar (24,198 reports)

Browse all side effects of Opdivo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Scar:

Scar (1,231 drugs)

Browse all the conditions that are associated with Scar:

Scar (1,431 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nivolumab (the active ingredients of Opdivo) and Opdivo (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.